

# Chemotherapy Induced Peripheral Neuropathy (CIPN): Epidemiology Forecasting Intelligence

<https://marketpublishers.com/r/C6379BFC609EN.html>

Date: February 2019

Pages: 50

Price: US\$ 2,500.00 (Single User License)

ID: C6379BFC609EN

## Abstracts

CmaxInsight's "Chemotherapy Induced Peripheral Neuropathy (CIPN)-Epidemiology Forecasting Intelligence" report provides a comprehensive analysis of the Chemotherapy Induced Peripheral Neuropathy (CIPN) epidemiology, providing the historical, current, and forecasted data for the United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan during the period from 2018-2028.

Our epidemiology services include:

Incidence and prevalence

Diagnosis rate, treatment rate and mortality patterns

Epidemiology-based forecasting and disease trends

Size of different patient segments in a disease area

Population based: disease occurrence, co-morbidities and treatment patterns

Geographic - Regional - Ethnic differences

Along with the epidemiological data, the report also includes:

Disease overview, causes, symptoms, classification, risk factor, pathophysiology, diagnosis and treatment

Patient treatment journey

Treatment algorithm and guidelines

Assesses the disease risk and burden

Highlights the unmet needs

Market driver and barrier

Growth opportunities and market trend analysis

## Methodology

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Epidemiology Forecast model analysis by a team of industry experts.

To generate accurate patient population estimates, utilizes a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies.

All of the sources used to generate the data and analysis have been identified in the report.

**Note:** Systematic review of the epidemiological literature is also provided for full transparency into research and methods. This report can be delivered to the clients within 4-5 business days.

## Contents

### **1. REPORT INTRODUCTION**

### **2. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN) EPIDEMIOLOGY OVERVIEW AT A GLANCE**

### **3. MARKET SHARE DISTRIBUTION OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN)**

### **4. DISEASE BACKGROUND AND OVERVIEW: CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN)**

- 4.1. Introduction
- 4.2. Signs and Symptoms
- 4.3. Etiology
- 4.4. Risk Factors
- 4.5. Pathophysiology
- 4.6. Diagnostic Landscape
  - 4.6.1. Diagnostic Practices
  - 4.6.2. Diagnostic Criteria
  - 4.6.3. Diagnostic Recommendations
- 4.7. Treatment Landscape
  - 4.7.1. Current Treatment Practices
  - 4.7.2. Treatment Algorithm
  - 4.7.3. Treatment Recommendations

### **5. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN) EPIDEMIOLOGY**

- 5.1. Key Findings
- 5.2. Assumptions & Rationale
- 5.3. 7MM Epidemiology

### **6. EPIDEMIOLOGY OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN) BY COUNTRIES**

### **7. UNITED STATES**

### 7.1. Assumptions and Rationale

### 7.2. Prevalent/Incident Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

### 7.3. Sub-Type Specific cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)\*

### 7.4. Sex- Specific Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)\*

### 7.5. Diagnosed Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

### 7.6. Treated Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

## 8. EU5

### 8.1. Germany

#### 8.1.1. Assumptions and Rationale

#### 8.1.2. Prevalent/Incident Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

#### 8.1.3. Sub-Type Specific cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)\*

#### 8.1.4. Sex- Specific Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)\*

#### 8.1.5. Diagnosed Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

#### 8.1.6. Treated Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

### 8.2. France

#### 8.2.1. Assumptions and Rationale

#### 8.2.2. Prevalent/Incident Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

#### 8.2.3. Sub-Type Specific cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)\*

#### 8.2.4. Sex- Specific Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)\*

#### 8.2.5. Diagnosed Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

#### 8.2.6. Treated Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

### 8.3. United Kingdom

#### 8.3.1. Assumptions and Rationale

#### 8.3.2. Prevalent/Incident Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

#### 8.3.3. Sub-Type Specific cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)\*

#### 8.3.4. Sex- Specific Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)\*

#### 8.3.5. Diagnosed Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

#### 8.3.6. Treated Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

### 8.4. Spain

#### 8.4.1. Assumptions and Rationale

#### 8.4.2. Prevalent/Incident Cases of Chemotherapy Induced Peripheral Neuropathy

(CIPN)

8.4.3. Sub-Type Specific cases of Chemotherapy Induced Peripheral Neuropathy

(CIPN)\*

8.4.4. Sex- Specific Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)\*

8.4.5. Diagnosed Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

8.4.6. Treated Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

8.5. Italy

8.5.1. Assumptions and Rationale

8.5.2. Prevalent/Incident Cases of Chemotherapy Induced Peripheral Neuropathy

(CIPN)

8.5.3. Sub-Type Specific cases of Chemotherapy Induced Peripheral Neuropathy

(CIPN)\*

8.5.4. Sex- Specific Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)\*

8.5.5. Diagnosed Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

8.5.6. Treated Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

## **9. JAPAN**

9.1. Assumptions and Rationale

9.2. Prevalent/Incident Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

9.3. Sub-Type Specific cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)\*

9.4. Sex- Specific Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)\*

9.5. Diagnosed Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

9.6. Treated Cases of Chemotherapy Induced Peripheral Neuropathy (CIPN)

## **10. UNMET NEEDS**

Appendix

Report Methodology

Sources Used

Disclaimer

About CmaxInsight

\*Indication Specific

Note: Certain sections of the table of contents would vary according to the availability of information.

## List Of Tables

### LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in 7MM

Table 2: Total Prevalent/Incident Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in United States

Table 4: Sub-Type Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in United States\*

Table 5: Sex- Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in United States\*

Table 6: Diagnosed Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in United States

Table 7: Treated Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in United States

Table 8: Prevalent/Incident Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Germany

Table 9: Sub-Type Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Germany\*

Table 10: Sex- Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Germany\*

Table 11: Diagnosed Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Germany

Table 12: Treated Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Germany

Table 13: Prevalent/Incident Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in France

Table 14: Sub-Type Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in France\*

Table 15: Sex- Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in France\*

Table 16: Diagnosed Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in France

Table 17: Treated Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in France

Table 18: Prevalent/Incident Cases of the Chemotherapy Induced Peripheral

Neuropathy (CIPN) in Italy

Table 19: Sub-Type Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Italy\*

Table 20: Sex- Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Italy\*

Table 21: Diagnosed Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Italy

Table 22: Treated Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Italy

Table 23: Prevalent/Incident Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Spain

Table 24: Sub-Type Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Spain\*

Table 25: Sex- Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Spain\*

Table 26: Diagnosed Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Spain

Table 27: Treated Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Spain

Table 28: Prevalent/Incident Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in UK

Table 29: Sub-Type Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in UK\*

Table 30: Sex- Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in UK\*

Table 31: Diagnosed Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in UK

Table 32: Treated Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in UK

Table 33: Prevalent/Incident Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Japan

Table 34: Sub-Type Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Japan\*

Table 35: Sex- Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Japan\*

Table 36: Diagnosed Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Japan

Table 37: Treated Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Japan

\*Indication Specific



## List Of Figures

### LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in 7MM

Figure 2: Total Prevalent/Incident Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in United States

Figure 4: Sub-Type Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in United States\*

Figure 5: Sex- Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in United States\*

Figure 6: Diagnosed Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in United States

Figure 7: Treated Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in United States

Figure 8: Prevalent/Incident Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Germany

Figure 9: Sub-Type Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Germany\*

Figure 10: Sex- Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Germany\*

Figure 11: Diagnosed Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Germany

Figure 12: Treated Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Germany

Figure 13: Prevalent/Incident Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in France

Figure 14: Sub-Type Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in France\*

Figure 15: Sex- Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in France\*

Figure 16: Diagnosed Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in France

Figure 17: Treated Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in United France

Figure 18: Prevalent/Incident Cases of the Chemotherapy Induced Peripheral

Neuropathy (CIPN) in Italy

Figure 19: Sub-Type Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Italy\*

Figure 20: Sex- Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Italy\*

Figure 21: Diagnosed Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Italy

Figure 22: Treated Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Italy

Figure 23: Prevalent/Incident Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Spain

Figure 24: Sub-Type Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Spain\*

Figure 25: Sex- Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Spain\*

Figure 26: Diagnosed Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Spain

Figure 27: Treated Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Spain

Figure 28: Prevalent/Incident Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in UK

Figure 29: Sub-Type Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in UK\*

Figure 30: Sex- Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in UK\*

Figure 31: Diagnosed Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in UK

Figure 32: Treated Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in UK

Figure 33: Prevalent/Incident Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Japan

Figure 34: Sub-Type Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Japan\*

Figure 35: Sex- Specific Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Japan\*

Figure 36: Diagnosed Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Japan

Figure 37: Treated Cases of the Chemotherapy Induced Peripheral Neuropathy (CIPN) in Japan

\*Indication Specific

## I would like to order

Product name: Chemotherapy Induced Peripheral Neuropathy (CIPN): Epidemiology Forecasting Intelligence

Product link: <https://marketpublishers.com/r/C6379BFC609EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C6379BFC609EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

